
This study compares the impact of the 3 different out-of-pocket maximums proposed in Congress and by the Medicare Payment Advisory Commission.
This study compares the impact of the 3 different out-of-pocket maximums proposed in Congress and by the Medicare Payment Advisory Commission.
Out-of-pocket (OOP) spending for specialty drugs is substantially higher in Medicare Part D compared with employer-sponsored insurance because of the Part D benefit design.
Published: August 18th 2025 | Updated: August 25th 2025
Published: August 19th 2025 | Updated: August 22nd 2025
Published: June 6th 2025 | Updated: August 18th 2025
Published: June 27th 2025 | Updated: July 1st 2025
Published: February 20th 2025 | Updated: February 21st 2025
Published: January 16th 2025 | Updated: January 29th 2025
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.